中国中医药信息杂志2024，Vol.31Issue(10)：142-148,7.DOI:10.19879/j.cnki.1005-5304.202403118
基于真实世界的百合固金汤对非小细胞肺癌放疗患者长期预后的影响
Effects of Baihe Gujin Decoction on the Long-term Prognosis of NSCLC Patients with Radiotherapy Based on Real World
摘要
Abstract
Objective To evaluate the effects of Baihe Gujin Decoction on long-term survival in patients with non-small cell lung cancer(NSCLC)receiving radiotherapy(RT)in the real world.Methods Retrospective data from patients with NSCLC receiving RT in the Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine(TCM)and data from patients in the Surveillance,Epidemiology and End Results(SEER)database were collected and grouped as the TCM+conventional Western medicine(CWM)cohort and CWM cohort,respectively.Propensity score matching(PSM)was used to balance confounders between groups.Kaplan-Meier curve and Cox regression model were used to estimate the effects of Baihe Gujin Decoction on survival outcomes of patients receiving RT.Results Totally 190 samples with a balance between groups were obtained using PSM.Overall survival(OS)analysis showed that the TCM+CWM cohort had significantly longer OS than the CWM cohort(P=0.004).Subgroup analysis showed that the Baihe Gujin Decoction was more advantageous in the characteristic population of age≥65 years(P=0.027),male(P=0.010),T3-T4 stage(P<0.001),N2-N3 stage(P=0.026),M1 stage(P<0.001),not receiving chemotherapy(P<0.001),and not undergoing surgery(P<0.001).Multivariate Cox regression confirmed that treatment group(P=0.003),T(P=0.003)and M stages(P=0.002)may be the independent prognostic factors for OS of NSCLC patients treated with RT.Conclusion Baihe Gujin Decoction probably can improve the long-term prognosis in NSCLC patients treatment with RT.关键词
真实世界研究/非小细胞肺癌/放疗/百合固金汤/生存期Key words
real-world research/non-small cell lung cancer/radiotherapy/Baihe Gujin Decoction/survival分类
中医学引用本文复制引用
郑鑫蓥,张惠勇,黄星,邱磊,方庆亮,鹿振辉,王蕾..基于真实世界的百合固金汤对非小细胞肺癌放疗患者长期预后的影响[J].中国中医药信息杂志,2024,31(10):142-148,7.基金项目
上海市自然科学基金(23ZR1463900) （23ZR1463900）
上海市卫生行业临床专项(20214Y0377) （20214Y0377）
上海市医学创新研究专项(21Y11922400) （21Y11922400）
